SciBase publishes information document regarding rights issue

SciBase's board has resolved a rights issue of approximately SEK 83 million and published the required information document, now registered with the Swedish Financial Supervisory Authority and available on the company's and Bergs Securities' websites. Trading in subscription rights runs 12–21 Jan 2026, subscription period 12–26 Jan 2026, with the expected outcome announced 27 Jan 2026; Bergs Securities and Birchtree Advisory act as financial advisors and Advokatfirman Schjødt as legal counsel. The raise is a routine equity financing for the Stockholm-based dermatology device developer (Nevisense, AI + EIS technology) and materially affects its near-term funding profile and shareholder dilution prospects.

Analysis

Market structure: SciBase’s SEK 83m rights issue (subscription 12–26 Jan; outcome 27 Jan) directly benefits underwriters/advisors and existing shareholders who subscribe; it dilutes non-participating holders and increases free float of subscription rights (tradeable 12–21 Jan). Expect 5–25% near-term downward pressure on the share vs. pre-announcement level depending on take-up; smaller, cash-constrained medtech peers face relative outflows as capital rotates to survival financings.

Risk assessment: Tail risks include a failed rights take-up forcing a bridge loan or deeper follow‑on (high-impact; low-probability if uptake <60%), ISP/FDI Act filings delaying strategic investors, or clinical/regulatory setbacks reducing commercialization upside. Immediate (days): volatility around rights trading; short-term (weeks): post‑issue price discovery; long-term (quarters): valuation hinges on revenue adoption and whether proceeds extend runway >12 months.

Trade implications: Direct plays — avoid initiating large long positions pre-outcome; if you hold, either subscribe pro rata to avoid >X% dilution or sell into the rights premium. Use rights trading window (12–21 Jan) to acquire exposure cheaply if rights price <10% of theoretical ex‑rights price; execute small directional bets (1–2% NAV) and use 30–60 day protective puts or put spreads to cap downside.

Contrarian angles: Consensus treats the raise as purely dilutive; overlooked is that limiting foreign participation (FDI/territory restrictions) can flood local rights onto market, creating a transient buying opportunity post-allocation. If take-up >80% and SEK 83m materially extends runway to ≥18 months, a rapid 15–40% rebound is possible — so prepare to add on confirmation (revenue or distributor ramp) rather than preemptively chasing the stock.

Key Decisions for Investors

• If you are an existing SciBase shareholder, subscribe pro rata during 12–26 Jan to avoid dilution unless you believe post‑money runway ≤12 months; maintain only if post‑issue implied cash runway ≥12–18 months or revenue growth target >30% YoY is realistic.
• Non‑holders: do not build a full-sized long before 27 Jan. Consider buying tradable subscription rights during 12–21 Jan only if rights trade at ≥10% discount to theoretical ex‑rights price; size at 0.5–1.5% NAV and hedge with 30–60 day put (10–15% OTM) or put spread.
• Speculative short: establish a small opportunistic short (0.5–1% NAV) if post‑issue take‑up <60% or if management signals need for immediate additional capital; cover on any sign of institutional support or confirmed >80% subscription.
• Reweight sector exposure: reduce micro‑cap Scandinavian medtech allocation by ~50% vs. benchmark and rotate into cash‑positive large-cap medtechs (e.g., Elekta EKTAb.ST, Getinge GETI-B.ST) with >12 months runway and positive EBITDA to cut idiosyncratic financing risk.